Inhaled amniotic fluid for lung scarring
Part of Lungs & breathing clinical trials.
This trial tests whether breathing in a mist of human amniotic fluid can help people with interstitial lung disease, a condition where lung tissue becomes scarred and stiff. It aims to see if this treatment is safe and might improve your breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 90 years old.
- You have been diagnosed with interstitial lung disease by a doctor.
- Your lung function tests show at least 45% of normal for one measure and 30% of normal for another.
- Your oxygen level is at least 92% while resting, and you use no more than 3 liters of oxygen per minute.
- You are not currently taking other treatments for interstitial lung disease, except oxygen or pulmonary rehab.
- You are not pregnant, and if you could become pregnant, you must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication (H01/hymecromone) to see if it can help people with progressive lung scarring (ILD). It lasts about 12 to 24 weeks and requires good lung function without needing oxygen at rest.
This trial tests whether a new treatment made from menstrual blood stem cells, given by injection, can help people with IPF, a condition that causes lung scarring and makes breathing harder. The study aims to see if the treatment can slow down the disease and improve lung function.
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
This study follows patients with chronic lung scarring (fibrosing interstitial lung disease) who are in the intensive care unit for severe breathing failure. It aims to better understand their condition and care, which may help improve future treatments.
This study tests an experimental treatment using tiny particles from human stem cells, given through a nebulizer (breathing mist). It aims to see if this treatment is safe and can help improve lung function in people with interstitial lung disease (lung scarring).
This study tests whether starting an early anti-scarring medication can help people with stable lung fibrosis. It aims to see if the treatment slows down the disease and improves quality of life.
Hear when a new Lung Diseases, Interstitial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.